WO2004019680A1 - 臓器、組織または細胞の保護および保存のための組成物およびその利用 - Google Patents
臓器、組織または細胞の保護および保存のための組成物およびその利用 Download PDFInfo
- Publication number
- WO2004019680A1 WO2004019680A1 PCT/JP2003/011127 JP0311127W WO2004019680A1 WO 2004019680 A1 WO2004019680 A1 WO 2004019680A1 JP 0311127 W JP0311127 W JP 0311127W WO 2004019680 A1 WO2004019680 A1 WO 2004019680A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polyphenol
- organ
- composition
- surgery
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/02—Preservation of living parts
- A01N1/0205—Chemical aspects
- A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
- A01N1/0226—Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/33—Cactaceae (Cactus family), e.g. pricklypear or Cereus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the protection and preservation of cells, tissues or organs.
- the present invention relates to a composition having a function of protecting and preserving organs, cells and tissues, and a use thereof.
- cells are stored frozen at very low temperature of 196 ° C, and when necessary, these frozen cells are rapidly thawed to obtain live cells.
- the survival rate after freezing and thawing depends on the cell type and the skill of the experimenter, but the survival rate of normal useful cells other than cancer, such as islets of Langerhans and hepatocytes, is extremely low, at most 10-30. %.
- organ transplantation With the recent advances in surgical techniques and immunosuppressants, the number of cases of organ transplantation is increasing. In this organ transplantation, it is ideal that the organ removed from the donor (donor) is immediately transplanted to the recipient (recipient), but transplantation surgery is not necessarily performed immediately. However, since transplant surgery is urgent, preserving precious organs is extremely important. At present, low-temperature preservation methods for suppressing metabolism of organs and perfusion preservation methods for maintaining metabolism are applied as organ preservation methods, and various preservation solutions used for them have been developed and clinically used. It has been applied. In addition, during surgery on organs such as the heart, it may be necessary to temporarily stop blood flow, but if cells, tissues and organs become ischemic and then reperfused, Free radicals cause damage to cells, tissues and organs.
- a preservative containing polyphenol is removed from a living body by adding it to various culture solutions or organ preservation solutions used as ordinary cell culture solutions.
- various culture solutions or organ preservation solutions used as ordinary cell culture solutions By keeping the isolated cells in a blocked state, the proliferative effect was suppressed and the storage period was greatly extended, or the functions of the preserved organs and the like could be maintained for a long period of time.
- a cardiac arrest fluid is perfused into the heart to artificially stop the heart, and during this period, the myocardium is in an ischemic state, and the heart function often decreases due to lack of oxygen. This can cause major damage to the myocardium during reperfusion after ischemic conditions. This is called reperfusion injury, and it can cause a fatal burden on patients, which is a major problem.
- polyphenols have been shown to play a role of preservation at the cell or tissue level, but at the higher level of organs, they also maintain that function, that is, perform the function of protection. That cannot be expected. This is because, for example, it is common knowledge that a tissue remains within 24 hours of functioning even if it is removed from the body, but in the case of an organ (for example, a heart), it is necessary to remove the organ before it dies. Therefore, removal of organs from brain death to cardiac arrest plays an important role. Thus, no composition has yet been identified that "protects" an organ, fibrous tissue or cell.
- the present invention has been attained, in part, by the inventors finding that polyphenols have unexpectedly significant protective effects on organs, tissues or cells.
- the present invention provides the following.
- composition for protecting and preserving an organ, tissue or cell comprising polyphenol.
- composition according to item 1 wherein the polyphenol is present in an amount effective for protection of the organ, tissue or cell in at least one of ischemia and reperfusion.
- composition according to item 2 wherein the ischemia or reperfusion occurs at the time of surgical or medical operation.
- composition according to item 1 wherein the protection is at the time of surgery, and the polyphenol is administered at any time before the operation or after reperfusion.
- composition according to item 4 wherein the administration is at least any time from about 2 weeks before the operation to the day of the operation.
- composition according to item 4 wherein the administration is performed at least after reperfusion.
- composition according to item 10 wherein the operation is a surgical operation.
- composition according to item 11 wherein the operation uses off-pump, PCI, catheter intervention or extracorporeal circulation.
- the surgical operation is an operation on an aorta, a coronary artery, or a valve.
- composition ⁇ according to item 1 wherein the organ, tissue or cell is an organ.
- composition according to item 1 wherein the organ includes skin, blood vessel, cornea, kidney, heart, liver, umbilical cord, intestine, nerve, lung, placenta, or knee.
- composition according to item 1, wherein the organ is selected from the group consisting of heart, brain, nerve and spinal cord.
- composition according to item 1 wherein the organ, tissue or cell is a mammal.
- composition according to item 1 wherein the organ, tissue or cell is human.
- composition according to item 1 which is a protective agent for an organ, tissue or cell.
- composition according to item 19 wherein the protection includes protection against ischemia.
- composition according to item 1 wherein the polyphenol is selected from the group consisting of catechins, tannins, pluanthocyanidins, and resveratrol.
- composition according to item 1 wherein the polyphenol has a hydroxy value of 2 to about 100.
- polyphenol includes an extract selected from the group consisting of tea extract, seaweed extract, aloe extract and wine extract, cactus extract and fruit extract. object.
- the polyphenol comprises a seaweed extract, composition c (29) wherein the polyphenylene of claim 1.
- Perilla Ichiru comprises tea extract composition of claim 1.
- a method for protecting an organ, tissue or cell in a subject comprising:
- polyphenol is selected from the group consisting of catechins, tannins, pluanthocyanidins, and resveratrol.
- polyphenol according to item 30 wherein the polyphenol includes an extract selected from the group consisting of a tea extract, a seaweed extract, an aloe extract, a wine extract, a cactus extract, and a fruit extract.
- an extract selected from the group consisting of a tea extract, a seaweed extract, an aloe extract, a wine extract, a cactus extract, and a fruit extract.
- the fibrous composition of the present invention protects cells, tissues or organs (turns metabolic function to a normal state) by directly or indirectly administering it to a living body. It can be an inhibitor.
- the composition of the present invention further comprises a polyphenol as an active ingredient, which is used in a surgical procedure to cut off the blood flow of organs, whereby the target organs are placed in a metabolic function-suppressed state by being administered to a living body in advance. It may be a function improver.
- composition of the present invention may be used in a surgical procedure to cut off the blood flow of organs by administering a metabolic function inhibitor containing polyphenol as an active ingredient to a living body in advance to thereby reduce the metabolic function of the target organs.
- the method for suppressing ischemic damage to organs which makes the normal state of the organ, is also a feature. More specifically, in one embodiment, The above-mentioned surgical procedure is a cardiac operation, the method of suppressing ischemic injury is characterized in that the target organ is the heart, and the above-mentioned administration conditions are oral and intravenous administration.
- the present invention provides a method for suppressing ischemic injury of organs, characterized in that the heart muscle is protected as 0.01 to 0.1 lg / Kg / day within 2 weeks from the day of surgery.
- FIG. 1 is an enlarged photograph of a myocardial pathological specimen showing a cross section of the heart of a control group rat and a polyphenol-administered group rat.
- FIG. 2 is a graph showing the relationship between left ventricular end systolic pressure and volume.
- FIG. 3 shows the results of immunopathological determination using 8-OHdG.
- Figure 4 is an enlarged photograph (control) of a pathological specimen showing vacuolar degeneration of the nucleus of cardiomyocytes.
- FIG. 5 is an enlarged photograph of a pathological specimen (vacuum administration of polyphenol) showing vacuole degeneration of the nucleus of cardiomyocytes.
- FIG. 6 is a diagram showing the localization of polyphenol in cells using FITC-labeled polyphenol.
- FIG. 7 shows the effect of polyphenol on heart weight after reperfusion. Description of the preferred embodiment
- polyphenol refers to a phenol having two or more hydroxyl groups in the same molecule, and is also referred to as a polyvalent phenol. It is called divalent phenol or trivalent phenol depending on the number of hydroxyl groups.
- C 6 H 4 (OH) 2 such as force tecohol, resorcin and hydroquinone is a divalent phenol
- phloroglucin C 6 H 3 (OH) 3 is a trivalent phenol.
- Polyphenols can be classified into flavonoids, hydrolyzable tannins, and other polyphenols according to certain taxonomies.
- Hydrolyzed tannins and bronthocyanines are collectively included in tannins (or tannic acids) '.
- the preferred polyphenols used herein are those which have already been approved by the authorities as foods or pharmaceuticals (including quasi-drugs, etc.). Examples of such a substance include, but are not limited to, tannic acid and albumin tannate, which are described in the Japanese Pharmacopoeia.
- tannin has a basic structure of polyoxyphenyl, and is a generic term for those which can obtain phenols and the like by alkali decomposition.
- Potassium melting separates pyrogallol tannins, which generate pyrogallol, and catechol tannins, which generate force techol.
- hydrolyzed tannins that are hydrolyzed to produce gallic acid and ellagic acid, and condensed tannins that polymerize to produce water-insoluble probafen.
- Hydrolyzed tannins often have a structure in which gallic acid, polyoxydiphenic acid, and the like are depsidically bonded to sugar.
- the condensed tannin is considered to be formed by polymerization of several molecules of catechin and leuco anthocyan.
- any type of tannin may be effective.
- the tannin can be tannic acid or albumin tannate. Tannic acid is a crude product of gallotannins and is also used as a medicine.
- Albumin tannate is a mixture of tannin and albumin, which is also used as a medicine.
- Flaponoids include chalcones, flavanones, flavones, flavonols, flavanonols, flavanols (catechins), isoflavones, anthocyans, benzalkumaranones, anthocyanidins, protocyanidines, etc. . Flaponoids have antioxidant properties, but their effect generally weakens as the number of phenolic hydroxyl groups decreases. Flavonoids have been noted for their anticancer effects.
- Such a flavonoid has the following structural formula.
- Chalcone is 1,3-diphenyl-2-propylene-1-one (1,3-diphenyl-2-propen-2-one). Yes, also called benzanolacetofenone.
- Chalcones include hydroxy derivatives of this chalcone. Examples of the chalcone include, but are not limited to, chalcone, butincholeobucin, isobutrin, carconocartamidine, isocartamine, carthamin, veginin, vegininin, and the like.
- flavanone is 2,3-dihydroflavone
- flavanones are derivatives thereof (eg, hydroxy derivatives and methoxy derivatives (especially 3, 5, 7, 3 ′). , 4, replaced by a digit))).
- Flavanones are mainly found in the plant kingdom (especially citrus) as glycosides. Flavanones include, but are not limited to, flavanone, pinocembrin, naringen, saliprubin, brunin, naringin, sachranetin, sakuranin, hesveletin, hesveridin, erythic thiol, matoistinol, etc.
- the "isoflavones” used in the above are 3-phenylchromones, and the isoflavones include derivatives and glycosides thereof.
- v Classes include, but are not limited to, daidzein, daidzin, genistein, genistin, etc., in addition to isoflavones.
- flavone is 2-fueurchromone (C 15 H 10 O 2 ), and flavone is a generic term for its derivatives (eg, hydroxy derivatives and methoxy derivatives). Flavones include, but are not limited to, flavone, chrysin, tringin, avigenin, cosmosin, aviin, luteolin, garteolin, dalcorteolin, and the like.
- flavonols as used herein, 3 - hydroxy Flavobacterium emissions (C 1 5 H 1 0 0 3), flavonols, derivatives thereof (e.g., glycoside, human Dorokishi derivatives Contact Yopi (Methoxy derivative).
- flaponols include, but are not limited to, kaempferol ⁇ ⁇ , triforine, astragarin, robinin, que ⁇ cetin, quercitrin, isoquercitrin, rutin, myricetin, myricitrin, and the like.
- flavanonol is a compound in which a hydroxyl group is bonded to the 3rd position of the C ring of flavanone, and flavanonols are a general term for derivatives thereof. Flavanonols include, but are not limited to, flavanonol, pinobanksin, alomadendrine, engeritin, fustin, taxifolin, austinolevin, amperoptin, and the like.
- “flavanol (catechin)” refers to a flavan in which a hydroxyl group is bonded to the 3-position of the C ring, and catechins are a generic term for derivatives thereof.
- catechins include catechin, gallocatechin, epicatechin, epigallocatechin, epicatechin gallate, epigallocatechin gallate, and bimolecularly polymerized theaflavins (for example, theaflavin, theaflavin 13-gallate, theaflavin, etc.).
- anticyanidin refers to a 2-phenylbenzopyrylium structure having a 4-6 value hydroxyl group bonded thereto (aglycone).
- the glycoside is called anthocyanin, and anthocyan is the name of both.
- Ben monkey Kumara non is also referred to as "Auron", is represented by C 1 5 H 1 0 O 2 .
- Benzalkumaranones are a generic term for their derivatives. Examples of benzalkumaranones include, but are not limited to, benzalcomaranone, snoreletin, sfrain, paracitrin leptosidine, leptosin, ssip cysidine, ssip isine, selnuoside, and the like.
- the organ targeted by the present invention may be any organ, and the tissue or cell targeted by the present invention may be derived from any organ or organ of an organism.
- organ or “organ” is used interchangeably, and a function of a living individual is localized and operated in a specific part of the individual, and the part is morphologically independent. Structure.
- organs consist of several tissues with a particular spatial arrangement, and tissues consist of many cells. Such organs or organs include those involved in the vasculature.
- the organs targeted by the present invention include skin, blood vessels, cornea, kidney, heart, liver, umbilical cord, intestine, nerve, lung, placenta, knee, brain, limb periphery, retina, and the like. But not limited to them.
- the organ targeted by the present invention includes a heart or an organ of the cranial nervous system. More preferably, the organ targeted by the present invention is a heart. In another embodiment, the organ targeted by the present invention may be a liver, a kidney, or the like.
- tissue refers to a cell population having substantially the same function and function or morphology in a multicellular organism.
- tissue Usually an "organization" Cell populations having the same origin but different origins may be referred to as tissues if they have the same function and Z or morphology. Therefore, when regenerating a tissue using the stem cells of the present invention, a cell population having two or more different origins can constitute one tissue.
- tissue is part of an organ. Animal tissues can be divided into epithelial, connective, muscle, and nervous tissues based on morphological, functional, or developmental evidence. Plants are classified into meristems and permanent tissues according to the stage of development of the constituent cells, and are classified into single tissues and composite tissues according to the type of the constituent cells.
- cell is defined in the broadest sense as used in the art, and is a constituent unit of a tissue of a multicellular organism, wrapped in a membrane structure that isolates the outside world, An organism that has self-renewal ability and has genetic information and its expression mechanism.
- Cells targeted in the present specification include cells in an in vivo state. Cells include, for example, epidermal cells, covering cells, tubule cells, hepatocytes, blood cells, cardiomyocytes, skeletal muscle cells, osteoblasts, skeletal myoblasts, nerve cells, vascular endothelial cells, pigment cells, Examples include smooth muscle cells, fat cells, bone cells, and chondrocytes.
- Cells can be classified according to their origin into stem cells derived from ectoderm, mesoderm and endoderm.
- the cells derived from the ectoderm mainly exist in the brain and include neural stem cells.
- Mesodermal-derived cells are mainly present in bone marrow, and include vascular stem cells, hematopoietic stem cells, mesenchymal stem cells, and the like.
- Endoderm-derived cells are mainly present in organs and include hepatic stem cells, knee stem cells, and the like.
- the somatic cells targeted by the present invention may be derived from any germ layer.
- the term "protection" of an organ, tissue or cell means to prevent the loss of the function of the organ, tissue or cell in a living body in vivo (in vivo), preferably Maintaining, more preferably improving.
- protection of the heart means protecting the heart from ischemic injury and the like so that cardiac function does not deteriorate.
- necrosis of cells due to ischemia There are various obstacles in the living body, such as the generation of free radicals during subsequent reperfusion, and protection of organs, tissues or cells from these attacks is included in the concept of protection.
- the term "preservation" of an organ, tissue or cell refers to maintaining or improving the state of the organ, tissue or cell outside a living body. Therefore, protection and preservation are different concepts. In particular, it is unpredictable that even a substance that has a preservation effect will perform the same function in a living body, so it cannot be said that it has a general protective effect.
- protection and preservation have the same characteristics in some aspects, but in preservation, it is often necessary to leave the storage for a long time, and in many cases, it takes a long time. It also differs in that it does not last for a long time because it affects the living body itself.
- ischemia or “ischemic state” refers to a state of local or insufficient blood flow of an organ or tissue. Impaired blood supply results in localized tissue death. When performing heart surgery, it is necessary to temporarily stop some or all of the blood flow, in which case it will at least temporarily become ischemic, and subsequent reperfusion will cause damage. Often occurs. Conventionally, protection during ischemia has been difficult.
- reperfusion refers to the resumption of blood flow after coronary artery occlusion has opened. Reperfusion results in reperfusion injury. Reperfusion injury is a myocardial injury that persists after coronary artery occlusion opens, often with arrhythmias. This is thought to be due to oxygen-derived free radicals.
- ischemic injury includes disorders that occur during ischemia and reperfusion, and include disorders or diseases caused by ischemic death, paralysis, heart failure, myocardial stunning, spinal palsy, retina.
- Disease, optic nerve disorder, ischemic cardiomyopathy, cerebral ischemic disorder, kidney Examples include, but are not limited to, ischemic disorders, organ ischemic disorders such as hepatic ischemic disorders, and the like.
- the “disease” targeted by the present invention can be any disease that causes tissue damage.
- diseases include, but are not limited to, for example, diseases of any organ.
- heart diseases include heart failure, myocardial infarction, and cardiomyopathy.
- the protection law of the present invention can be applied to protection of organs other than the heart.
- Heart failure refers to a condition in which the heart itself is impaired, such as cardiac insufficiency, circulatory insufficiency, or reduced contractile force, so that the necessary amount and quality of blood cannot be circulated to organs throughout the body.
- Heart failure is an end-stage symptom of heart disease such as myocardial infarction and cardiomyopathy. Severe heart failure is defined as severe heart failure, also known as end-stage heart failure.
- Myocardial infarction is a disease in which ischemic necrosis occurs in the perfusion area due to severe stenosis or occlusion due to various lesions of the coronary artery.
- classifications include, for example, time-course classification, morphological classification (intramyocardial area, location, size of death, etc.), myocardial death pattern, ventricular reconstruction after infarction, hemodynamics.
- Classification (related to treatment, prognosis, etc.), classification by clinical severity. Here, those with high severity are particularly called severe myocardial infarction.
- Cardiomyopathy is a general term for diseases caused by structural and functional abnormalities of the myocardium, and secondary cardiomyopathy secondary to underlying diseases such as hypertension, metabolic disorder, and ischemia, and apparently Is classified as idiopathic cardiomyopathy that develops without underlying disease.
- Myocardial hypertrophy, fibrosis, degeneration, etc. are recognized as pathological changes.
- prophylaxis or “prevention” refers to the ability of a disease or disorder to prevent such a condition from occurring before such condition is caused. Cause the condition to occur or delay the occurrence of that condition Means Therefore, the protection method of the present invention can be used for prevention or in combination with another prevention method.
- the term “treatment” refers to preventing the worsening of a disease or disorder when such a condition occurs, preferably maintaining the status quo, more preferably reducing, It preferably refers to fluctuating.
- the protection methods of the present invention may be used in therapy.
- off-pump refers to performing a treatment without using a cardiopulmonary bypass when used during a surgical operation. Off-pump surgery is used for coronary artery surgery. In the case of off-pump surgery, temporary ischemia occurs locally by blocking blood vessels to be anastomosed for about 10 to 30 minutes, so dysfunction at that time is sometimes a problem.
- extracorporeal circulation As used herein, “extracorporeal circulation”, “pump” or “cardiopulmonary bypass” are used interchangeably and refer to performing treatment using a cardiopulmonary bypass. Even with cardiopulmonary bypass, problems during ischemia and reperfusion occur, so ischemic injury is a problem in any surgery.
- “surgery” may be surgical or medical.
- surgical procedures include, but are not limited to, AC bypass, valvuloplasty, valve replacement, aortic surgery, living donor liver transplantation, living donor kidney transplantation, brain dead liver transplantation, and heart transplantation.
- it may be an operation on the aorta, coronary artery or valve.
- the medical operation include PCI (for example, PTCA) using a balloon catheter or the like, catheter intervention, PTA for various blood vessels, and the like. Balloon catheters often fall into the category of off-pump surgery.
- the cell, fibrous tissue or organ used in the present invention may be a cell derived from any organism (eg, a multicellular organism of any kind (eg, an animal (eg, a vertebrate, an invertebrate)), a plant (eg, a Monocots, dicots, etc.) Good
- cells derived from vertebrates eg, black eels, smelt eel, chondrichthyes, teleosts, amphibians, reptiles, birds, mammals, etc.
- mammals eg, monopores
- the pharmaceutically acceptable carrier contained in the pharmaceutical composition of the present invention includes any substance known in the art.
- Such pharmaceutically acceptable carriers include, but are not limited to, antioxidants, preservatives, colorants, flavors, and diluents, emulsifiers, suspending agents, solvents, fillers. Bulking agents, buffers, delivery vehicles, diluents, excipients and Z or pharmaceutical adjuvants.
- a pharmaceutical composition of the invention comprises one or more (eg, a mixture) polyphenols, together with one or more physiologically acceptable carriers, excipients or diluents. It is administered in the form of a composition.
- suitable vehicles may be water for injection, physiological solutions, or artificial cerebrospinal fluid, which may be supplemented with other materials common in compositions for parenteral delivery. is there.
- Exemplary suitable carriers include neutral buffered saline, or saline mixed with serum albumin.
- the product is formulated as a lyophilizate using appropriate excipients (eg, sucrose).
- excipients eg, sucrose
- Other standard carriers, diluents and excipients can be included as desired.
- Other exemplary compositions include a Tris buffer at pH 7.0-8.5 or an acetate buffer at pH 4.0-5.5, which may further comprise sorbitol or an appropriate salt thereof. May include substitutes.
- the pharmaceutical composition of the present invention can be administered parenterally. Alternatively, the composition is It can be administered intravenously or subcutaneously. When administered systemically, the pharmaceutical composition used in the present invention may be in the form of a pyrogen-free, pharmaceutically acceptable aqueous solution.
- the preparation of such pharmaceutically acceptable compositions is within the skill of those in the art, provided that considerable attention is paid to the survival, pH, isotonicity, stability, etc. of the cells, tissues or organs. Is within.
- the pharmaceutical formulation of the present invention may contain a physiologically acceptable carrier, excipient or stabilizer (Japanese Pharmacopoeia 14th edition or its latest edition (including supplements), as required), ceutical Sciences, 18th Edition, AR Gennaro, ed., Mack Pub 1 ising Company, 1990, etc.) and a cell composition having a desired degree of purity. Thereby, it can be prepared and stored in the form of a lyophilized cake or aqueous solution.
- a physiologically acceptable carrier Japanese Pharmacopoeia 14th edition or its latest edition (including supplements), as required
- ceutical Sciences 18th Edition, AR Gennaro, ed., Mack Pub 1 ising Company, 1990, etc.
- a cell composition having a desired degree of purity
- an acceptable carrier, excipient, or stabilizer is non-toxic to the recipient, and is preferably inert at the dosage and concentration used, And include: phosphate, citrate, or other organic acids; antioxidants (eg, ascorbic acid); low molecular weight polypeptides; proteins (eg, serum albumin, gelatin or immunoglobulin) Hydrophilic polymers (eg, polyvinylpyrrolidone); amino acids (eg, glycine, glutamine, asparagine, arginine or lysine); monosaccharides, disaccharides and other carbohydrates (including glucose, mannose, or dextrin); chelating agents (Eg, EDTA); sugar alcohol (eg, mannitol) Or sorbitol); salt-forming agents (eg, sodium); and / or non-ionic surface activators (eg, Tween, p1 uronic or polyethylene glycol (PEG)).
- antioxidants eg, ascorbic acid
- the present invention provides a composition for protecting and preserving an organ, tissue or cell, comprising polyphenol.
- the polyphenol is present at a pharmacologically or medically (or agriculturally or veterinarily) effective concentration.
- the present inventors were interested several years ago in this polyphenol, particularly in its inhibitory action on cancer cell growth, and examined various properties. As a result, it was found that ordinary antioxidants (for example, superoxide dismutase (SOD ), And non-enzymatic specific properties not found in vitamin E, vitamin C, daltathione, carotenoids, flavonoids, sugars, iron chelators, uric acid, albumin, etc.) Shows soluble amphipathicity, has excellent protein-adsorbing properties, has extremely low cytotoxicity, has an antioxidant activity more than 10 times that of SOD, and has never been known before. Can be controlled freely.
- SOD superoxide dismutase
- polyphenols are excellent in various physiological activities, for example, anticancer activity, antioxidant activity, antibacterial and antiviral activity. Although studies on the effects of this polyphenol on cell growth have already been reported, most of them inhibit the growth of cancer cells.
- Green tea polyphenols have various actions such as antioxidant action, deodorant action, and antibacterial action, and also have anti-corrosive properties and other physiological activities. .10, Green tea polyphenol, Mitsuo Uemura, Confectionery Technical Center, Sanyusha). However, no effect of polyphenol on the preservation of animal cells and organs has been suggested.
- polyphenol has an effect of preserving cells and tissues in vitro, and filed a patent application.
- isolated cells or excised living tissues and organs are immersed in a preservation solution containing polyphenol to preserve them in a blocked state, or to administer a preservative as a postoperative treatment. By doing so, the prevention and recovery of various injuries to subsequent organs were aimed at.
- the concentration in the preservative solution or the blood concentration is kept within an effective range, it is expected that the generation of free radicals and their effects in cells in contact with them can be suppressed, and by confirming the actual effects It was a view of the completion of the invention. Therefore, its effect is exerted on cells, organs, etc. by maintaining a certain blood concentration by immersion in the preservation solution or by administration, but naturally it ischemic state In this case, no effect was exhibited, and the effect was a transient effect irrespective of the mode of administration, and a sustained effect thereafter was not expected.
- the present inventors have found that when polyphenols are administered to a living body, their effects on cells, tissues, and organs do not necessarily show the progress of the effects as compared to when they are immersed in a storage solution containing polyphenol. Rather, they found that when administered in vivo, they had a protective effect on cells, tissues or organs, and thus came to the present invention.
- a subject is continuously administered a polyphenol having these activities for a certain period of time, even if these cells, tissues and organs are subsequently collected and removed and cut off from the bloodstream, these cells or organs will remain intact. It remains shut off and then re-establishes (or maintains) its function in subsequent reperfusions without damaging free radicals. Therefore, it can be said that the present invention can provide an effect which has not been achievable conventionally, particularly in terms of organ protection during ischemia.
- Polyphenols are generally readily available in products with a purity of 60% or more, and the polyphenols of the present invention as preservatives for cells and organs can be used in products with a purity of 60% or more. % Or more refined products are more suitable. Of course, higher purity is more effective.
- the polyphenols contained in the composition of the present invention are included irrespective of the purity of the polyphenol.
- the polyphenols are preferably catechins or tannins.
- catechins known as 3,3,4,5,7-flavopentol, catecholamines having a 3,4-dihydroxyphenyl skeleton, and nonoreadrenaline , Adrenaline and dopamine are included, and catechins containing epigallocatechingallate as a main component are particularly preferable.
- Examples of other preferred polyphenols include tannic acid.
- Typical tannic acid for example, is tannic acid, in which eight gallic acid groups are arranged around a glucose residue and on the same plane, and two more gallic acid groups are bonded vertically.
- the central part of the compound is not necessarily limited to glucose, but may be a cellulosic compound, such as galedic acid didebuside obtained by hydrolyzing tannic acid. . Therefore, in the present invention, the polyphenol may be a mixture or a single product. In a preferred embodiment, the polyphenol is selected from the group consisting of catechins, tannins, pluantocyanidin and resveratrol.
- the polyphenol comprises at least tecchins or tannic acid. In a more preferred embodiment, the polyphenols include epigallocatechin gallate. In another preferred embodiment, the polyphenol comprises a polyphloroglucinol conjugate. Tea extracts, seaweed extracts and wine extracts, cactus extracts and fruit extracts are preferred.
- the hydroxy value of the polyphenol used in the present invention may be any one as long as it is defined in the polyphenol, but usually the hydroxy value is from 2 to about 100, more preferably 3 or more. And more preferably 4 or more.
- the polyphenols used herein can be extracted from various foods. Such foods include, for example, tea, wine, chocolate, cacti, seaweed, vegetables (onions (outer tan skin), aloe extract parsley leaves, white vegetables, etc.), citrus fruits (Wenzhou oranges, Daikan, bonkan peel, summer tangerine peel, grapefruit, lemon, etc.), fruits such as apples, cereals (such as cocoa, soybeans, buckwheat, wheat), and dahlia flowers, but not limited to these .
- the polyphenol contains an extract selected from the group consisting of tea extract, seaweed extract, fruit extract, sapoten extract and wine extract.
- the polyphenol comprises a seaweed extract. In another embodiment, the polyphenol comprises a tea extract.
- the polyphenol is administered such that it is present in at least one of the phases of ischemia and reperfusion in an amount effective to protect an organ, fibrous tissue or cells.
- the polyphenol may be administered preoperatively or at the time of ischemia or reperfusion.
- administration will be for at least about 2 weeks before surgery (or At least one week before surgery, at least 3 days before surgery, at least 2 days before surgery, at least 1 day before surgery), or any day on the day of surgery, more preferably from about 2 weeks before surgery.
- Administration may be performed periodically until the day of surgery (eg, 0.1 to 100 mg / kg body weight, eg, 40 mg Z kg body weight once daily).
- the administering occurs at least during ischemia. In yet another embodiment, at least during reperfusion. In yet another embodiment, it is performed after reperfusion.
- the interval between administrations is not limited to these preferred embodiments.
- the frequency of applying the treatment method of the present invention to a subject (or patient) also depends on the purpose of use, target disease (type, severity, etc.), One of ordinary skill in the art can easily determine such factors in consideration of age, weight, sex, medical history, and course of treatment.
- the frequency includes, for example, administration three or four times a day (for example, 1 to 2 weeks of Yong Yong) to once every two weeks.
- the administration frequency may be changed as appropriate while monitoring the progress.
- compositions of the present invention are administered orally or parenterally using a method well known in the art.
- parenteral administration methods can be, for example, intravenous, intramuscular, subcutaneous, intradermal, mucosal, rectal, vaginal, topical to the affected area, dermal, etc.
- Formulations for such administration may be provided in any form.
- preparation forms include, for example, liquid preparations, injections, and sustained-release preparations.
- the amount of the polyphenol used in the treatment method of the present invention depends on the purpose of use, the target disorder, surgery and disease (type, severity, etc.), age, weight, sex, medical history, cell morphology or type of the patient. A person skilled in the art can easily determine this in consideration of such factors.
- the ischemia or reperfusion can occur during a surgical or medical procedure. Therefore, the present invention has an enormous effect in cases where an ischemic condition occurs in a surgical operation or a medical operation.
- the protection of the organ, tissue or cells may be during surgery.
- the polyphenol may be administered at any time before surgery or after reperfusion, more preferably at the above-described dosing frequency, interval, and timing.
- the surgery may be in particular a surgery. Therefore, what is protected by the present invention may be an organ.
- Surgery can use off-pumps, PCI, catheter intervention or extracorporeal circulation, and cardiac surgery includes, but is not limited to, aortic, coronary or valvular surgery.
- an organ may be, for example, a blood vessel, cornea, kidney, heart, liver, umbilical cord, intestine, nerve, lung, placenta or scutellum.
- such organs include, but are not limited to, brain, nerve, heart, spinal cord, and the like.
- the polyphenol-containing composition of the present invention can be used for protection or preservation of essentially any living organism as long as it is an organism.
- the organism is a vertebrate or invertebrate, and more preferably, the organism is a vertebrate (e.g., eel, eel, chondrichthyes, teleosts, amphibians, reptiles, birds, mammals)
- Cells derived from mammals e.g., animals
- mammals e.g., monotremes, marsupials, oligodonts, skin wings, wing-hands, carnivores, carnivores, and longnoses
- mammals e.g., monotremes, marsupials, oligodonts, skin wings, wing-hands, carnivores, carnivores, and longnoses
- Hoofed horses artiodactyla, dundents, squamata, squids, cetaceans,
- compositions of the present invention may be aimed at protecting organs, tissues or cells. This protection preferably includes, but is not limited to, protection during ischemia.
- the compositions of the present invention may be intended for preserving organs, tissues or cells.
- the present invention provides a method for protecting an organ, tissue or cell in a subject, the method comprising: 1) exposing polyphenol to the organ, fibrous tissue or cell. I will provide a.
- polyphenol may be administered to the subject in an amount effective to protect the organ, tissue or cell at least during one of ischemia and reperfusion.
- the timing of administration of polyphenol in the protection method of the present invention is, as described above, as long as it is administered in such an amount that an effective concentration is present at the time of ischemia or reperfusion, or at the time of occurrence of injury after reperfusion.
- Any form of administration is possible.
- it is administered to the subject at any time before the operation and after the reperfusion.
- the administration is at least anywhere from about 2 weeks before surgery to the day of surgery, more preferably at least one of at the time of ischemia or reperfusion.
- administration may be performed after reperfusion.
- relief or healing of the disorder may be achieved. If administered before reperfusion, it will have a prophylactic effect, but may also have the effect of reducing the damage if it occurs.
- the administration may be oral or parenteral.
- Oral preoperative treatment is preferred for patient comfort.
- V preferably performed parenterally during surgery. This is because patients are usually under anesthesia during surgery and it is difficult for patients to take them.
- subject or “subject” refers to an organism to which treatment (eg, treatment, prevention, prognosis) is applied, and is also referred to as “patient”.
- the “patient,” “subject,” or “subject” may be any organism to which the present invention applies.
- the "patient”, “subject” or “subject” is a human.
- the protection of the above method is intended for surgery.
- the method of the present invention is effective.
- the operation may be a surgical operation or a medical operation.
- the method of the invention is particularly suitable for surgery. Such surgeries include off-pump, P
- the surgery can be CI, catheter intervention or extracorporeal circulation, and the surgery can be aortic, coronary or valvular surgery.
- the protection method of the present invention can be, in a preferred embodiment, a method of protecting an organ.
- This organ includes, but is not limited to, skin, blood vessels, cornea, kidney, heart, liver, umbilical cord, intestine, nerve, lung, placenta or knee.
- said organ is selected from the group consisting of heart, brain, nerve and spinal cord.
- the organ can be a heart.
- the finding of a protective effect in the heart can be a particularly special effect.
- the target organ, tissue or cell in the protection method of the present invention may be of any organism, but is preferably a mammal, more preferably a human.
- the protection method of the present invention may include at least one of protection during ischemia and reperfusion.
- the polyphenol used in the protection method of the present invention is as described above, and various types can be used.
- the present invention provides a method for preserving an organ, a tissue or a cell, comprising: 1) retaining the organ, tissue or cell in a fluid containing polyphenol.
- a method for preserving an organ, a tissue or a cell comprising: 1) retaining the organ, tissue or cell in a fluid containing polyphenol.
- the present invention provides the use of a polyphenol for the manufacture of a medicament for protecting or preserving an organ, tissue or cell, wherein the medicament comprises porifenol.
- the medicament of the present invention when the medicament of the present invention is embodied as a package, instructions can be attached. Such instructions may be available from the competent authority of the country in which the invention is implemented.
- compositions of the present invention are usually administered under the supervision of a physician, but depending on the intended use (eg, preservation of the heart), may be carried out under the supervision of a physician, if the local regulatory authority and the law permit. Can be performed without supervision.
- composition or medicament of the present invention may further comprise other agents.
- an agent can be any agent known in pharmacy.
- the composition or medicament of the present invention may contain more than one other agent.
- agents include, for example, those listed in the latest editions of the Japanese Pharmacopoeia, the United States Pharmacopeia, and other countries.
- Such an agent may preferably have an effect on the organ of the organism in question.
- drugs that produce favorable effects in surgery can be co-administered. Examples of such drugs include, but are not limited to, thrombolytics, vasodilators, tissue activators, teco-lamine, PDE III inhibitors, calcium antagonists, beta blockers, steroids, etc. Dare ,.
- the amount of polyphenol to be administered in the composition of the present invention or the medicament is determined in consideration of the type, purpose of use, target disease (type, severity, etc.), age, weight, sex, and medical history of the patient. Thus, those skilled in the art can easily determine.
- the amount of polyphenol to be administered in the composition or medicament of the invention is between 0.1 and 100 Omg / kg / day, preferably between 1 and 1 Omg / kg / day or between 10 and 100 mg Zkg. Day, etc.
- SD rats were obtained from Shimizu Experimental Materials and bred in a spirit of animal welfare in accordance with the guidelines for animal experiments set by Kyoto University.
- the SD rats were divided into two groups. One group received polyphenol and the other group received distilled water as a control.
- the polyphenol to be administered was prepared from green tea as follows. The green tea leaves were pulverized, extracted with low-temperature hot water, and then separated and purified using a water-ethanol-based chromatograph. Green tea polyphenols contain potassium techin and tannic acid as main components. The green tea polyphenol used in this example contained a large amount of epigallocatechin gallate (epigallocatechin gallate).
- the rats in each group shown in Table 1 were anesthetized with ether and pentobarbital, the heart was excised by midline thoracotomy, and ice-cooled Krebs-Henseleit Buffer (NaCl 0.6895 g, KC1 0.0343 g, MgS0 4 0. 145g, CaCl 2 - was 2H 2 0 0. 368g, KH 2 P0 4 0. 164g, NaHC0 3 2. 10 g, and immersed quickly in Glucose 0. 188g / 100m 1).
- Krebs-Henseleit Buffer NaCl 0.6895 g, KC1 0.0343 g, MgS0 4 0. 145g
- CaCl 2 - was 2H 2 0 0. 368g, KH 2 P0 4 0. 164g, NaHC0 3 2. 10 g, and immersed quickly in Glucose 0. 188g / 100m 1).
- the excised heart was weighed, immediately attached to a Langendorff apparatus, and pre-perfused with a Krebs Henseleit Buffer saturated with a mixed gas of 95% oxygen and 5% carbon dioxide as a perfusate. Then, a latex balloon was connected from the left atrium to the left ventricle via the mitral valve. After 20 minutes of preperfusion, myocardial perfusate was collected and measured for myocardial deviating enzymes (G0T, GPT, CPK, CPK-MB, LDH, Toloponin-T).
- the balloon inserted into the left ventricle was connected to a pressure monitor via a transducer to measure the pressure-time relationship (dP / dt). Further left The intraventricular balloon was expanded, and the pressure-volume relationship (ESPVR / EDPVR) was measured.
- Cardiac arrest fluid was additionally administered at a dose of 10 ml / Kg every 30 minutes, and the cardiac arrest was continued for a total of 90 minutes.
- the cardiac arrest fluid in the heart was washed away at a flow rate of Krebs-Henseleit Buffer 10 m 1 / Kg (hot shot), and then Krebs saturated with a mixed gas of 95% oxygen and 5% carbon dioxide as in pre-perfusion.
- -Reperfusion was performed using Henseleit Buffer as the perfusate.
- bradycardia in which the heart rate during reperfusion is 85% or less of the preperfusion.
- Example 1 instead of preoperative administration, a green tea polyphenol composition was concurrently administered during ischemia. The administered formulation was sterilized before administration. The results revealed that edema prevention after reperfusion was significantly achieved (data not shown). In addition, it was observed that cardiac contractility was maintained, oxidative stress was reduced, and cardiomyocytes were protected. However, compared to the preoperative administration in Example 1, the effect was slightly lower. (Example 3: administration during reperfusion)
- Example 1 instead of preoperative administration, a green tea polyphenol composition was simultaneously administered during reperfusion. The administered formulation was sterilized before administration. The results revealed that edema prevention after reperfusion was significantly achieved (data not shown). In addition, it was observed that cardiac contractility was maintained, oxidative stress was reduced, and cardiomyocytes were protected. However, the effect was slightly lower than the preoperative administration in Example 1 or the administration during ischemia in Example 2. Therefore, it is clear that administration before surgery is more effective than administration during actual ischemia or reperfusion. (Example 4: Intracellular accumulation of polyphenol) To examine from another viewpoint the phenomenon that polyphenols had an organ-protecting effect even when administered before surgery, we examined whether polyphenols were accumulated in cells.
- the green tea polyphenol used in Example 1 was labeled with FITC, and orally administered using the same protocol to examine the distribution of the polyphenol in the cells.
- the heart of a rat (Wistar strain, 380 g) was excised under anesthesia, and the storage effect was compared and examined.
- the cells were washed with UW solution and stored by cooling for 48 hours.
- the UW solution was washed at the time of nephrectomy with a preservation solution obtained by further adding polyphenol (10 mg / ml), and was similarly cooled and stored for 48 hours. Thereafter, continuous perfusion was performed for 90 minutes using a cardiac perfusion apparatus, and the perfusion rate, dp / dt, and ESPVR) were compared.
- cardiac damage was remarkably reduced in the polyphenol-added system of the present invention, as compared to the preserved kidney containing only UW solution used as a control.
- the present invention is applied to open heart surgery (cardiovascular surgery using cardiopulmonary bypass) and off-pump bypass surgery (surgery to perform coronary artery bypass surgery without using a heart-lung machine and leaving a heartbeat).
- open heart surgery cardiac surgery using cardiopulmonary bypass
- off-pump bypass surgery surgery to perform coronary artery bypass surgery without using a heart-lung machine and leaving a heartbeat.
- Examples 1 to 6 are performed using a seaweed extract instead of the tea extract. It was prepared as follows from commercially available seaweed as seaweed. The vasa was pulverized into fine powder, extracted with hot water at low temperature, and the polyphenols were separated and purified using a water-ethanol chromatograph.
- the protective effect on the heart is observed when administered preoperatively as described in Example 1.
- azapolyphenol fibrin is administered during ischemia.
- the results show that prevention of edema after reperfusion is significantly achieved.
- cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 3 the azapolyphenol composition is co-administered during reperfusion.
- the results show that prevention of edema after reperfusion has been significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 6 when an experiment was performed on the brain and liver as in Example 5, similar results were obtained. When observing the extracorporeal preservation effect of the heart as described in Example 6, it is also observed that there is a preservation effect.
- the aloe vera commercially available was prepared as follows. After aloe was pulverized and subjected to low-temperature hot water extraction, polyphenols were separated and purified using a water-ethanol type chromatograph.
- the protective effect on the heart is observed when administered preoperatively as described in Example 1.
- Example 3 the Aloe polyphenol composition is co-administered during reperfusion.
- the results show that prevention of edema after reperfusion has been significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 10 Wine extract
- Red wine polyphenol contains flavonol and catechin as main components.
- the protective effect on the heart is observed when administered preoperatively as described in Example 1.
- Example 2 the red wine polyphenol composition is administered at the time of ischemia.
- the results show that prevention of edema after reperfusion is significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- the red wine polyphenol composition is then co-administered during reperfusion as described in Example 3.
- the results show that significant prevention of edema after reperfusion has been achieved.
- cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 11 cactus extract
- the protective effect on the heart is observed when administered preoperatively as described in Example 1.
- Example 2 a sabotimo fenol composition is administered during ischemia.
- the results show that prevention of edema after reperfusion is significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 3 co-administration of the sabotimo rifenol composition during reperfusion.
- the results show that significant prevention of edema after reperfusion has been achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 4 Observation of the accumulation of polyphenol in the body as described in Example 4 shows that the distribution of polyphenol is localized in the cell membrane of the myocardium.
- Example 1 to 6 are performed using a fruit extract instead of the tea extract.
- a commercially available fruit was prepared from grapes as follows. The fruits were pulverized and extracted with low-temperature hot water, and then the polyphenols were separated and purified using a water / ethanol chromatograph.
- the protective effect on the heart is observed when administered preoperatively as described in Example 1.
- 1 preventive effects of edema after reperfusion 2 maintenance of cardiac contractility; 3 reduction of acid-induced stress; 4 protection of cardiomyocytes.
- Example 2 the fruit polyphenol composition is administered during ischemia. As a result, it is clear that prevention of edema after reperfusion has been significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- Example 3 the fruit polyphenol composition is co-administered during reperfusion, as described in Example 3.
- the results show that prevention of edema after reperfusion is significantly achieved. It is also observed that cardiac contractility is maintained, oxidative stress is reduced, and cardiomyocytes are protected.
- the effect of polyphenol to protect and protect organs, tissues or cells was confirmed.
- Such an effect can be applied in surgery and the like, and is used as a medicament, and is particularly useful as enhancing the flexibility of surgery.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004532782A JPWO2004019680A1 (ja) | 2002-08-30 | 2003-08-29 | 臓器、組識または細胞の保護および保存のための組成物およびその利用 |
EP03791435A EP1535514A4 (en) | 2002-08-30 | 2003-08-29 | COMPOSITION FOR THE PROTECTION OF ORGANS, TISSUE OR CELLS AND THEIR USE |
AU2003261860A AU2003261860A1 (en) | 2002-08-30 | 2003-08-29 | Composition for protecting organ, tissue or cell and utilization thereof |
US10/526,165 US20060116333A1 (en) | 2002-08-30 | 2003-08-29 | Composition for protecting organ, tissue or cell and utilization thereof |
US12/396,735 US20090170929A1 (en) | 2002-08-30 | 2009-03-03 | Composition for the Protection and Preservation of Organs, Tissues or Cells and the Use Thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002255979 | 2002-08-30 | ||
JP2002/255979 | 2002-08-30 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/396,735 Division US20090170929A1 (en) | 2002-08-30 | 2009-03-03 | Composition for the Protection and Preservation of Organs, Tissues or Cells and the Use Thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004019680A1 true WO2004019680A1 (ja) | 2004-03-11 |
Family
ID=31972930
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/011127 WO2004019680A1 (ja) | 2002-08-30 | 2003-08-29 | 臓器、組織または細胞の保護および保存のための組成物およびその利用 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20060116333A1 (ja) |
EP (2) | EP1535514A4 (ja) |
JP (1) | JPWO2004019680A1 (ja) |
AU (1) | AU2003261860A1 (ja) |
WO (1) | WO2004019680A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009221128A (ja) * | 2008-03-14 | 2009-10-01 | Seizo Fujikawa | 臓器保存液および臓器保存方法 |
JP2009542607A (ja) * | 2006-06-29 | 2009-12-03 | ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ | 臓器保存液 |
WO2013047665A1 (ja) * | 2011-09-29 | 2013-04-04 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
WO2014010685A1 (ja) * | 2012-07-11 | 2014-01-16 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
JP2016204667A (ja) * | 2010-03-04 | 2016-12-08 | 国立大学法人北海道大学 | カテキン型タンニンを含有する不凍性液体及びガラス化液 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005072523A2 (en) | 2004-02-02 | 2005-08-11 | I.M.T. Interface Multigrad Technology Ltd. | Biological material and methods and solutions for preservation thereof |
EP1711214A1 (en) | 2004-02-02 | 2006-10-18 | Interface Multigrad Technology (IMT) Ltd. | Device for directional cooling of biological matter |
ATE460947T1 (de) | 2004-06-07 | 2010-04-15 | Core Dynamics Ltd | Verfahren zur sterilisation von biologischen präparaten |
US8037696B2 (en) | 2004-08-12 | 2011-10-18 | Core Dynamics Limited | Method and apparatus for freezing or thawing of a biological material |
EP1909565A2 (en) | 2005-08-03 | 2008-04-16 | Interface Multigrad Technology (IMT) Ltd. | Somatic cells for use in cell therapy |
WO2007034851A1 (ja) * | 2005-09-22 | 2007-03-29 | Morinaga Milk Industry Co., Ltd. | 内臓脂肪蓄積抑制剤 |
DE102007035642A1 (de) * | 2007-07-30 | 2009-02-12 | Grietje Beck | Substanzen zur Protektion von Zellen und Geweben gegen Schädigung durch ungünstige Bedingungen |
DE102008012908A1 (de) | 2008-03-06 | 2009-09-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Methode zum anti-inflammatorischen und anti-ödematösen Schutz von explantiertem biologischen Material bis zu seiner Transplantation in Patienten |
US10575515B2 (en) * | 2010-05-04 | 2020-03-03 | The General Hospital Corporation | Methods and compositions for preserving tissues and organs |
RU2535036C1 (ru) * | 2013-09-26 | 2014-12-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ КПССЗ" СО РАМН) | Способ презервирования миокарда при трансплантации |
CN105532648B (zh) * | 2016-02-16 | 2018-01-12 | 云南省畜牧兽医科学院 | 一种小反刍动物精液冷冻稀释液 |
CN107593685B (zh) * | 2017-08-11 | 2020-04-14 | 同济大学 | 马尾松树皮提取物在制备移植器官保存液中的应用 |
US11647993B2 (en) * | 2017-12-22 | 2023-05-16 | Research Triangle Institute | Oral fluid collector |
CN108742255A (zh) * | 2018-05-29 | 2018-11-06 | 安吉席丫丫竹木有限公司 | 护肤擦手纸巾 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344602A (ja) * | 1999-06-02 | 2000-12-12 | Mg Seiyaku Kk | 動物の細胞または臓器の保存剤およびその保存方法。 |
WO2002001952A1 (fr) * | 2000-07-05 | 2002-01-10 | Hiromi Wada | Fluide de preservation pour cellules et tissus |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2651132B1 (fr) * | 1989-08-30 | 1993-01-08 | Pacific Chem Co Ltd | Agents de protection des cellules contre les especes chimiques a oxygene actif et leur preparation. |
FR2699818B1 (fr) * | 1992-12-24 | 1995-02-03 | Oreal | Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko. |
FR2740684B1 (fr) * | 1995-10-13 | 1998-01-02 | Dietetique Comp Gen De | Composition prophylactique absorbable ayant un effet protecteur contre les ondes electromagnetiques a effet ionisant ou non ionisant |
US20020127286A1 (en) * | 1996-10-24 | 2002-09-12 | Mathis-Heinrich Kreuter | Method for the treatment of human or animal cells, tissue cultures and/or organs outside the human or animal body |
CH690816A5 (de) * | 1996-10-24 | 2001-01-31 | Flachsmann Ag Emil | Verwendung eines Teil- oder Vollextrates aus nicht fermentierter Camellia sinensis L. zur Herstellung eines Medikamentes, eines Medizinproduktes, eines kosmetischen Präparates oder eines Nahrungsergänzungsproduktes. |
JP3977889B2 (ja) * | 1997-02-07 | 2007-09-19 | 株式会社アミノアップ化学 | 蕎麦殻抽出物を有効成分とする薬剤 |
JPH10287605A (ja) * | 1997-04-11 | 1998-10-27 | Tohoku Denshi Sangyo Kk | ポリフェノール化合物の測定方法及びその測定装置 |
US6319523B1 (en) * | 2000-06-29 | 2001-11-20 | James H. Zhou | Composition and method for inhibiting oral bacteria |
KR20020055735A (ko) * | 2000-12-29 | 2002-07-10 | 이성룡 | ()에피갈로카테킨 갈레이트(egcg)를 유효성분으로하는 전뇌허혈성 신경세포손상 예방 또는 치료제 |
JP2002205913A (ja) * | 2001-01-10 | 2002-07-23 | Ichimaru Pharcos Co Ltd | 化粧料組成物 |
JP2003267801A (ja) * | 2002-03-12 | 2003-09-25 | Pharmafoods Kenkyusho:Kk | 保存剤用組成物及び該組成物を含有する動物の細胞または臓器の保存剤 |
-
2003
- 2003-08-29 EP EP03791435A patent/EP1535514A4/en not_active Withdrawn
- 2003-08-29 EP EP10012787A patent/EP2269449A3/en not_active Withdrawn
- 2003-08-29 JP JP2004532782A patent/JPWO2004019680A1/ja active Pending
- 2003-08-29 WO PCT/JP2003/011127 patent/WO2004019680A1/ja active Application Filing
- 2003-08-29 US US10/526,165 patent/US20060116333A1/en not_active Abandoned
- 2003-08-29 AU AU2003261860A patent/AU2003261860A1/en not_active Abandoned
-
2009
- 2009-03-03 US US12/396,735 patent/US20090170929A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000344602A (ja) * | 1999-06-02 | 2000-12-12 | Mg Seiyaku Kk | 動物の細胞または臓器の保存剤およびその保存方法。 |
WO2002001952A1 (fr) * | 2000-07-05 | 2002-01-10 | Hiromi Wada | Fluide de preservation pour cellules et tissus |
Non-Patent Citations (1)
Title |
---|
See also references of EP1535514A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009542607A (ja) * | 2006-06-29 | 2009-12-03 | ザ ユニヴァーシティ コート オブ ザ ユニヴァーシティ オブ エディンバラ | 臓器保存液 |
JP2009221128A (ja) * | 2008-03-14 | 2009-10-01 | Seizo Fujikawa | 臓器保存液および臓器保存方法 |
JP2016204667A (ja) * | 2010-03-04 | 2016-12-08 | 国立大学法人北海道大学 | カテキン型タンニンを含有する不凍性液体及びガラス化液 |
WO2013047665A1 (ja) * | 2011-09-29 | 2013-04-04 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
WO2014010685A1 (ja) * | 2012-07-11 | 2014-01-16 | 石原産業株式会社 | 生物材料の低温保存用の保存剤及び低温での生物材料の保存方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2004019680A1 (ja) | 2006-01-05 |
EP2269449A3 (en) | 2011-03-16 |
EP1535514A1 (en) | 2005-06-01 |
AU2003261860A1 (en) | 2004-03-19 |
US20090170929A1 (en) | 2009-07-02 |
EP1535514A4 (en) | 2008-10-08 |
US20060116333A1 (en) | 2006-06-01 |
EP2269449A2 (en) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20090170929A1 (en) | Composition for the Protection and Preservation of Organs, Tissues or Cells and the Use Thereof | |
US6410052B1 (en) | Tea catechins in sustained release formulations as cancer specific proliferation inhibitors | |
US6528042B1 (en) | Compositions of flavonoids for use as cytoprotectants and methods of making and using them | |
US20020132845A1 (en) | Compositions and methods for the prevention and treatment of tissue ischemia | |
US6410061B1 (en) | Tea catechins as cancer specific proliferation inhibitors | |
EP2934511B1 (en) | Compositions for the treatment of gastrointestinal spasms | |
JP5706467B2 (ja) | 抗再吸収及び骨構築食事サプリメント及び使用方法 | |
CN101553137B (zh) | 具有高多酚含量的苹果 | |
US20060105069A1 (en) | Pharmaceutical and therapeutic compositions derived from Garcinia mangostana L plant | |
US20100068315A1 (en) | Composition Comprising an Extract of Gramineae Plant for the Prevention and Treatment of Ischemic Diseases and Degenerative Brain Diseases and the Use Thereof | |
CN107126440A (zh) | 含酚类组分和过氧化氢的制剂作为抗毒剂的用途 | |
JP2013529685A (ja) | レスベラトール含有組成物および使用方法 | |
Karaaslan et al. | Protective effect of grape seed extract against ischaemia/reperfusion injury in a rat epigastricflap model | |
EP1072265A1 (en) | Use of plant polyphenols for treating iron overload | |
US20020192314A1 (en) | Dietary supplement compositions | |
CA2465438A1 (en) | Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells | |
JP2010124821A (ja) | 抗菌性保存液 | |
WO2013147585A1 (en) | A composition having antiviral activity against flavivirus | |
US20130109641A1 (en) | Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases | |
KR101879398B1 (ko) | 망고스틴 추출물 및 프로폴리스 추출물을 포함하는 골형성 촉진용 조성물 및 이의 제조방법 | |
Mahmoudvand et al. | In vitro and ex vivo antiparasitic Effect of Rheum ribes L. extract against the hydatid cyst protoscoleces | |
KR101681980B1 (ko) | Colona auricaulata 추출물을 포함하는 당뇨합병증의 예방 또는 치료용 조성물 | |
US20060135446A1 (en) | Composition for improving blood fluidity | |
EP1100539B1 (de) | Wirkstoffkombination insbesondere zur prophylaxe und therapie von ischämischen organschäden und reperfusionssyndromen | |
RU2795879C1 (ru) | Композиция фиточая |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004532782 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003791435 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003791435 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006116333 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10526165 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10526165 Country of ref document: US |